A recent update of 3 consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma shows a sizeable group of patients surviving in continuous complete remission

Tarella, C; Ladetto, M; Benedetti, F; Vitolo, U; Pulsoni, A; Patti, C; Callea, V; Rambaldi, A; Piccin, A; Devizzi, L; Musso, M; Iannitto, E; Spedini, P; Liberati, Am; Ciceri, Fabio; Gallamini, A; Rodeghiero, F; Gini, G; De Crescenzo, A; Di Raimondo, F; Levis, A; Chisesi, T; Petrone, T; Scalabrini, Dr; Rossi, G; Carella, Am; Parvis, G; Majolino, I; Passera, R; Ruella, M; Pileri, A; Gianni, Am; Corradini, P.